SCHEMBL4144380

SCHEMBL4144380

Nc1sc2c(c1C(=O)Nc1ccc(Cl)cc1)CCCCC2

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 4/20 0.72
ALOX12 P18054 1/20 0.72
ANO1 Q5XXA6 4/20 0.66
TDP1 Q9NUW8 1/20 0.66
MAPT P10636 6/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
TP53 P04637 2/20 0.60
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
KDM4E B2RXH2 3/20 0.59
ALDH1A1 P00352 3/20 0.59
HPGD P15428 3/20 0.59
HSD17B10 Q99714 3/20 0.59
TSHR P16473 2/20 0.59
CASP1 P29466 1/20 0.59
CASP7 P55210 1/20 0.59
RXFP1 Q9HBX9 1/20 0.59
FLT3 P36888 1/20 0.56
ADORA1 P30542 1/20 0.55
TNF P01375 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28711032 0.99 ALOX15 (0.74) ALOX15ALOX12ANO1TDP1MAPT
SCHEMBL20340287 0.96 ALOX15 (0.70) ALOX15ALOX12ANO1TDP1MAPT
SCHEMBL16681664 0.85 ALOX15 (0.73) ALOX15ALOX12ANO1MAPTSMN1; SMN2
SCHEMBL721000 0.84 ALOX15 (1.00) ALOX15ALOX12ANO1TDP1MAPT
SCHEMBL4380481 0.84 MAPT (0.66) ALOX15ALOX12TDP1MAPTSMN1; SMN2
SCHEMBL4147929 0.82 ANO1 (0.73) ANO1MAPTSMN1; SMN2TP53MEN1
SCHEMBL17529331 0.81 TAAR1 (0.73) ALOX15ALOX12ANO1TDP1MAPT
SCHEMBL20339091 0.81 ANO1 (0.56) ALOX15ALOX12ANO1TDP1MAPT
SCHEMBL4139730 0.81 ANO1 (0.72) ANO1MAPTSMN1; SMN2TP53MEN1
SCHEMBL4153860 0.81 TDP1 (0.97) ALOX15ALOX12TDP1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-06-04 US claimed
EP-1802634-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-07-04 EP claimed
WO-2006044826-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO claimed
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-06-04 US disclosed
EP-1802634-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-07-04 EP disclosed
WO-2006044826-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents TP53, BRDT, VHL ALOX15 2402/4885ALOX12 2078/4885ANO1 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.